Wedbush Weighs in on Fusion Pharmaceuticals Inc.'s Q3 2023 Earnings (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Analysts at Wedbush boosted their Q3 2023 EPS estimates for Fusion Pharmaceuticals in a note issued to investors on Wednesday, August 9th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.38) per share for the quarter, up from their prior estimate of ($0.43). The […]

Related Keywords

United States ,Canada ,Raymond James ,Fusion Pharmaceuticals Price Performance ,Institutional Investors Weigh In On Fusion Pharmaceuticals ,News Ratings For Fusion Pharmaceuticals Daily ,Hermes Inc ,Nasdaq ,Renaissance Technologies ,Citadel Advisors ,Fusion Pharmaceuticals ,Fusion Pharmaceuticals Inc ,Fusion Pharmaceuticals Company Profile ,Millennium Management ,Free Report ,Fusion Pharmaceutical ,Get Free Report ,Pharmaceuticals Inc ,Fusion Pharmaceuticals Daily ,Nasdaq Fusn ,Fusn ,Medical ,Earnings Estimates ,Wedbush ,